glp-1 consumer behavior Weighing the Impacts of Usage GLP-1 Medication Effect on Food

The first of these trials, the STEP 1 trial, compared 2.4 mg of weekly semaglutide plus lifestyle intervention with placebo plus lifestyle intervention for 68 weeks in obese nondiabetic patients, and the result showed a clinically significant and sustained average weight loss among the semaglutide group (14.9%) and a difference of 12.4% compared to the placebo and lifestyle group (2.4% mean weight loss) [29]

Frequent urination Increased urinary frequency is commonly reported during semaglutide treatment, but the mechanism is usually benign

Do not freeze the medication

When food stays in the stomach longer, it can lead to a feeling of over-fullness or queasiness

Proper titration minimizes side effect severity with either medication

Instead, these FDA-approved medications work primarily by reducing appetite, slowing gastric emptying, and decreasing caloric intake